BusinessBioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with AchondroplasiaBy Nasdaq OMXDec 12, 2016, 1:29 PM UTC
BusinessBioMarin Announces Third Quarter 2016 Financial ResultsBy Nasdaq OMXOct 27, 2016, 8:07 PM UTC
BusinessBioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 MeetingBy Nasdaq OMXOct 19, 2016, 9:01 PM UTC
BusinessUK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia ABy Nasdaq OMXOct 13, 2016, 8:01 PM UTC
BusinessBioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ETBy Nasdaq OMXOct 11, 2016, 12:30 PM UTC
BusinessBioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta TherapeuticsBy Nasdaq OMXSep 21, 2016, 12:54 PM UTC
BusinessBioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten DiseaseBy Nasdaq OMXSep 15, 2016, 12:38 PM UTC
BusinessBioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten DiseaseBy Nasdaq OMXSep 6, 2016, 8:06 PM UTC
